Completed PHASE2 INTERVENTIONAL 2-arm NCT00535028

A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)

A Phase IIa Study To Investigate The Effects of AER 001 on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.

Sponsor: Aerovance, Inc.

Conditions Allergic Asthma

Interventions AER 001 placebo

Updated 4 times since 2017 Last updated: Sep 21, 2007 Started: Jan 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00535028, this PHASE2 trial focuses on Allergic Asthma and remains completed. Sponsored by Aerovance, Inc., it has been updated 4 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aerovance, Inc.
Quintiles, Inc.

Data source: Aerovance, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• 6 Newcomen Street London, United Kingdom